Nationwide Fund Advisors boosted its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 1.3% during the first quarter, Holdings Channel reports. The institutional investor owned 393,350 shares of the medical equipment provider’s stock after buying an additional 5,190 shares during the period. Nationwide Fund Advisors owned 0.91% of ABIOMED worth $49,247,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in ABMD. Palo Alto Investors LLC raised its stake in shares of ABIOMED by 1.0% in the fourth quarter. Palo Alto Investors LLC now owns 1,903,584 shares of the medical equipment provider’s stock worth $214,496,000 after buying an additional 19,200 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of ABIOMED by 4.3% in the third quarter. BlackRock Fund Advisors now owns 1,631,879 shares of the medical equipment provider’s stock worth $209,827,000 after buying an additional 66,809 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of ABIOMED by 1.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,177,198 shares of the medical equipment provider’s stock worth $151,364,000 after buying an additional 16,224 shares in the last quarter. William Blair Investment Management LLC raised its stake in shares of ABIOMED by 36.0% in the fourth quarter. William Blair Investment Management LLC now owns 1,029,366 shares of the medical equipment provider’s stock worth $115,989,000 after buying an additional 272,428 shares in the last quarter. Finally, Brown Capital Management LLC raised its stake in shares of ABIOMED by 16.2% in the fourth quarter. Brown Capital Management LLC now owns 701,811 shares of the medical equipment provider’s stock worth $79,080,000 after buying an additional 97,847 shares in the last quarter. Institutional investors and hedge funds own 92.67% of the company’s stock.
Shares of ABIOMED, Inc. (NASDAQ:ABMD) traded down 0.14% during mid-day trading on Friday, hitting $125.03. 177,820 shares of the stock were exchanged. ABIOMED, Inc. has a 52-week low of $92.03 and a 52-week high of $132.95. The firm has a market cap of $5.43 billion, a price-to-earnings ratio of 116.96 and a beta of 0.51. The stock has a 50-day moving average price of $123.21 and a 200 day moving average price of $116.67.
ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings data on Thursday, January 26th. The medical equipment provider reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.05. The business had revenue of $114.70 million for the quarter, compared to analysts’ expectations of $112.71 million. ABIOMED had a net margin of 11.63% and a return on equity of 12.35%. The business’s revenue was up 33.1% on a year-over-year basis. During the same quarter last year, the company earned $0.23 EPS. On average, equities research analysts expect that ABIOMED, Inc. will post $1.18 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Nationwide Fund Advisors Has $49.247 Million Position in ABIOMED, Inc. (ABMD)” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2486102/nationwide-fund-advisors-has-49-247-million-position-in-abiomed-inc-abmd.html.
ABMD has been the subject of a number of research analyst reports. BTIG Research reiterated a “buy” rating and issued a $170.00 price target on shares of ABIOMED in a research note on Sunday, January 8th. Piper Jaffray Companies upgraded shares of ABIOMED from a “neutral” rating to an “overweight” rating and set a $145.00 price target for the company in a research note on Thursday, April 6th. Leerink Swann lifted their price target on shares of ABIOMED from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, March 30th. Zacks Investment Research lowered shares of ABIOMED from a “hold” rating to a “sell” rating in a research note on Thursday, January 5th. Finally, TheStreet upgraded shares of ABIOMED from a “c+” rating to a “b-” rating in a research note on Tuesday, February 21st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $151.00.
In other news, VP Andrew J. Greenfield sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 17th. The shares were sold at an average price of $124.00, for a total transaction of $1,240,000.00. Following the sale, the vice president now owns 66,307 shares of the company’s stock, valued at approximately $8,222,068. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 10.00% of the stock is owned by company insiders.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.